236 related articles for article (PubMed ID: 38416763)
1. Association of lipid-lowering drugs with osteoarthritis outcomes from a drug-target Mendelian randomization study.
Ma W; Chen H; Zhang Z; Xiong Y
PLoS One; 2024; 19(2):e0293960. PubMed ID: 38416763
[TBL] [Abstract][Full Text] [Related]
2. Effects of genetically proxied lipid-lowering drugs on acute myocardial infarction: a drug-target mendelian randomization study.
Xiao W; Li Y; Zhuang Z; Song Z; Wang W; Huang N; Dong X; Jia J; Liu Z; Zhao Y; Qi L; Huang T
Lipids Health Dis; 2024 Jun; 23(1):163. PubMed ID: 38831433
[TBL] [Abstract][Full Text] [Related]
3. Causal effects of circulating lipids and lipid-lowering drugs on the risk of urinary stones: a Mendelian randomization study.
Tan Z; Hong J; Sun A; Ding M; Shen J
Front Endocrinol (Lausanne); 2023; 14():1301163. PubMed ID: 38107516
[TBL] [Abstract][Full Text] [Related]
4. Assessing the causal associations of different types of statins use and knee/hip osteoarthritis: A Mendelian randomization study.
Chen X; Huang X; Liu Y; Zhang Z; Chen J
PLoS One; 2024; 19(4):e0297766. PubMed ID: 38648228
[TBL] [Abstract][Full Text] [Related]
5. Using genetic variants to evaluate the causal effect of cholesterol lowering on head and neck cancer risk: A Mendelian randomization study.
Gormley M; Yarmolinsky J; Dudding T; Burrows K; Martin RM; Thomas S; Tyrrell J; Brennan P; Pring M; Boccia S; Olshan AF; Diergaarde B; Hung RJ; Liu G; Legge D; Tajara EH; Severino P; Lacko M; Ness AR; Davey Smith G; Vincent EE; Richmond RC
PLoS Genet; 2021 Apr; 17(4):e1009525. PubMed ID: 33886544
[TBL] [Abstract][Full Text] [Related]
6. Associations between Genetically Proxied Inhibition of Lipid-Lowering Drug Targets and Serum Micronutrients among Individuals of European Descent: A Mendelian Randomization Study.
He JY; Zhang X; Wang K; Lv WQ
J Nutr; 2022 May; 152(5):1283-1290. PubMed ID: 35349717
[TBL] [Abstract][Full Text] [Related]
7. Causal effects of circulating lipids and lipid-lowering drugs on the risk of epilepsy: a two-sample Mendelian randomization study.
Liang Z; Zhao L; Lou Y; Liu S
QJM; 2023 Jun; 116(6):421-428. PubMed ID: 36964718
[TBL] [Abstract][Full Text] [Related]
8. Associations between lipid-lowering drugs and pregnancy and perinatal outcomes: a Mendelian randomization study.
Wang R; Zhao J; Li L; Huo Y
J Hypertens; 2024 Apr; 42(4):727-734. PubMed ID: 38230624
[TBL] [Abstract][Full Text] [Related]
9. Association of lipid-lowering drugs with COVID-19 outcomes from a Mendelian randomization study.
Huang W; Xiao J; Ji J; Chen L
Elife; 2021 Dec; 10():. PubMed ID: 34866576
[TBL] [Abstract][Full Text] [Related]
10. Association between genetically proxied PCSK9 inhibition and prostate cancer risk: A Mendelian randomisation study.
Fang S; Yarmolinsky J; Gill D; Bull CJ; Perks CM; ; Davey Smith G; Gaunt TR; Richardson TG
PLoS Med; 2023 Jan; 20(1):e1003988. PubMed ID: 36595504
[TBL] [Abstract][Full Text] [Related]
11. Effect of blood lipids and lipid-lowering therapies on osteoarthritis risk: A Mendelian randomization study.
Wang Z; Liu M; Zhou Y; Shao H; Yang D; Huang Y; Deng W
Front Med (Lausanne); 2022; 9():990569. PubMed ID: 36438033
[TBL] [Abstract][Full Text] [Related]
12. Associations of Lipids and Lipid-Lowering Drugs with Risk of Vascular Dementia: A Mendelian Randomization Study.
Zhang X; Geng T; Li N; Wu L; Wang Y; Zheng D; Guo B; Wang B
Nutrients; 2022 Dec; 15(1):. PubMed ID: 36615727
[TBL] [Abstract][Full Text] [Related]
13. Causal Associations of Circulating Lipids with Osteoarthritis: A Bidirectional Mendelian Randomization Study.
Meng H; Jiang L; Song Z; Wang F
Nutrients; 2022 Mar; 14(7):. PubMed ID: 35405941
[TBL] [Abstract][Full Text] [Related]
14. Causal relationship between osteoporosis and osteoarthritis: A two-sample Mendelian randomized study.
Lin L; Luo P; Yang M; Wang J; Hou W; Xu P
Front Endocrinol (Lausanne); 2022; 13():1011246. PubMed ID: 36339427
[TBL] [Abstract][Full Text] [Related]
15. Genetically proxied therapeutic inhibition of lipid-lowering drug targets and risk of rheumatoid arthritis disease: a Mendelian randomization study.
Qiao L; Lv S; Meng K; Yang J
Clin Rheumatol; 2024 Mar; 43(3):939-947. PubMed ID: 38198113
[TBL] [Abstract][Full Text] [Related]
16. Genetically instrumented LDL-cholesterol lowering and multiple disease outcomes: A Mendelian randomization phenome-wide association study in the UK Biobank.
Pham K; Mulugeta A; Lumsden A; Hyppӧnen E
Br J Clin Pharmacol; 2023 Oct; 89(10):2992-3004. PubMed ID: 37208559
[TBL] [Abstract][Full Text] [Related]
17. The causal association between bone mineral density and risk of osteoarthritis: A Mendelian randomization study.
Jiang L; Jiang Y; Wang A; Wu C; Shen Y
Front Endocrinol (Lausanne); 2022; 13():1021083. PubMed ID: 36714576
[TBL] [Abstract][Full Text] [Related]
18. Causal effects of lipid-lowering therapies on aging-related outcomes and risk of cancers: a drug-target Mendelian randomization study.
Chen H; Tang X; Su W; Li S; Yang R; Cheng H; Zhang G; Zhou X
Aging (Albany NY); 2023 Dec; 15(24):15228-15242. PubMed ID: 38127052
[TBL] [Abstract][Full Text] [Related]
19. Association of lipid-lowering drug targets with risk of cutaneous melanoma: a mendelian randomization study.
Miao L; Miao T; Zhang Y; Hao J
BMC Cancer; 2024 May; 24(1):602. PubMed ID: 38760735
[TBL] [Abstract][Full Text] [Related]
20. Association of lipid-modifying therapy with risk of obstructive sleep apnea: A drug-target mendelian randomization study.
Zou J; Qi S; Sun X; Zhang Y; Wang Y; Li Y; Zhao ZH; Lei D
Toxicol Appl Pharmacol; 2024 Apr; 485():116909. PubMed ID: 38521370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
